| Previous Close | 81.05 |
| Open | 80.79 |
| Bid | 81.02 x 900 |
| Ask | 81.25 x 900 |
| Day's Range | 80.03 - 81.02 |
| 52 Week Range | 65.25 - 92.64 |
| Volume | 6,657,998 |
| Avg. Volume | 9,625,520 |
| Market Cap | 204.919B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 19.74 |
| EPS (TTM) | 4.10 |
| Earnings Date | Oct. 27, 2020 |
| Forward Dividend & Yield | 2.44 (3.01%) |
| Ex-Dividend Date | Sep. 14, 2020 |
| 1y Target Est | 94.41 |
- Reuters
Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors
Bristol Myers Squibb Co raised its annual profit forecast on Thursday on hopes of a recovery in demand for its hospital-administered drugs, which had dropped as patients stayed away from doctors' offices due to the COVID-19 pandemic. The U.S. drugmaker said it expects demand from new patients and for its products administered by doctors to start recovering in the third quarter and fully recovery in the fourth quarter. Other companies such as Pfizer Inc and Bristol's close rival Merck & Co also expect medical visits to return to normal by the fourth quarter.
- Business Wire
Merck Animal Health Completes Acquisition of IdentiGEN
Merck Animal Health Completes Acquisition of IdentiGEN
- Business Wire
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for NASH
